News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
737,511 Results
Type
Article (42269)
Company Profile (192)
Press Release (695040)
Multimedia
Podcasts (100)
Webinars (22)
Section
Business (234932)
Career Advice (2067)
Deals (35713)
Drug Delivery (137)
Drug Development (81795)
Employer Resources (173)
FDA (16639)
Job Trends (15045)
News (347944)
Policy (32880)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (2)
2027 Genetown Standard (3)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2631)
Accelerated approval (56)
ADA (44)
Adcomms (29)
Allergies (193)
Alliances (49690)
ALS (228)
Alzheimer's disease (1866)
Antibody-drug conjugate (ADC) (529)
Approvals (17131)
Artificial intelligence (741)
ASCO (327)
Autoimmune disease (352)
Automation (63)
Bankruptcy (366)
Best Places to Work (11664)
BIO (70)
BIOSECURE Act (20)
Biosimilars (239)
Biotechnology (126)
Bladder cancer (205)
Brain cancer (75)
Breast cancer (807)
Cancer (6372)
Cardiovascular disease (512)
Career advice (1758)
Career pathing (45)
CAR-T (358)
CDC (58)
Celiac Disease (3)
Cell therapy (972)
Cervical cancer (56)
Clinical research (71737)
Collaboration (2236)
Commercialization (1)
Company closure (5)
Compensation (1533)
Complete response letters (88)
COVID-19 (2770)
CRISPR (119)
C-suite (1266)
Cystic fibrosis (158)
Data (8739)
Decentralized trials (3)
Denatured (31)
Depression (179)
Dermatology (102)
Diabetes (674)
Diagnostics (7059)
Digital health (65)
Diversity (13)
Diversity, equity & inclusion (45)
Drug discovery (367)
Drug pricing (205)
Drug shortages (31)
Duchenne muscular dystrophy (311)
Earnings (92418)
Editorial (68)
Employer branding (21)
Employer resources (155)
Events (121003)
Executive appointments (1140)
FDA (20725)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (22)
Frontotemporal dementia (36)
Funding (1877)
Gene editing (251)
Generative AI (63)
Gene therapy (759)
GLP-1 (1100)
Government (4774)
Grass and pollen (6)
Guidances (421)
Healthcare (19214)
Hematology (192)
HIV (90)
Huntington's disease (64)
IgA nephropathy (114)
Immunology and inflammation (304)
Immuno-oncology (107)
Indications (222)
Infectious disease (3138)
Inflammatory bowel disease (222)
Inflation Reduction Act (14)
Influenza (144)
Intellectual property (321)
Interviews (325)
IPO (16719)
IRA (50)
Job creations (3663)
Job search strategy (1454)
JPM (59)
Kidney cancer (21)
Labor market (112)
Layoffs (584)
Leadership (42)
Legal (7993)
Liver cancer (103)
Longevity (35)
Lung cancer (842)
Lymphoma (481)
Machine learning (65)
Management (61)
Manufacturing (1177)
Marketing (5)
MASH (210)
Medical affairs (1)
Medical device (14143)
Medtech (14324)
Mergers & acquisitions (20324)
Metabolic disorders (1665)
mRNA (235)
Multiple sclerosis (202)
NASH (17)
Neurodegenerative disease (474)
Neuropsychiatric disorders (110)
Neuroscience (3535)
Neurotech (1)
NextGen: Class of 2026 (6555)
Non-profit (4569)
Now hiring (83)
Obesity (765)
Opinion (298)
Ovarian cancer (242)
Pain (272)
Pancreatic cancer (355)
Parkinson's disease (397)
Partnered (36)
Patents (651)
Patient recruitment (788)
Peanut (67)
People (60111)
Pharmaceutical (47)
Pharmacy benefit managers (33)
Phase 1 (22372)
Phase 2 (31602)
Phase 3 (23508)
Pipeline (10061)
Policy (333)
Postmarket research (2576)
Preclinical (9521)
Press Release (64)
Prostate cancer (340)
Psychedelics (59)
Radiopharmaceuticals (351)
Rare diseases (1205)
Real estate (5996)
Recruiting (71)
Regulatory (25985)
Reports (56)
Research institute (2439)
Resumes & cover letters (360)
Rett syndrome (46)
RNA editing (25)
RSV (90)
Schizophrenia (184)
Series A (319)
Series B (235)
Service/supplier (7)
Sickle cell disease (122)
Special edition (25)
Spinal muscular atrophy (192)
Sponsored (48)
Startups (3670)
State (2)
Stomach cancer (18)
Supply chain (134)
Tariffs (87)
The Weekly (67)
Vaccines (1158)
Venture capital (123)
Weight loss (487)
Women's health (138)
Worklife (21)
Date
Last 7 days (400)
Last 30 days (1816)
Last 365 days (30400)
2026 (16834)
2025 (30214)
2024 (35179)
2023 (40139)
2022 (51279)
2021 (55814)
2020 (54215)
2019 (46704)
2018 (35158)
2017 (32237)
2016 (31643)
2015 (37709)
2014 (31446)
2013 (26527)
2012 (28756)
2011 (29406)
2010 (27431)
Location
Africa (749)
Alabama (97)
Alaska (7)
Arizona (368)
Arkansas (14)
Asia (40112)
Australia (6606)
California (14112)
Canada (4006)
China (1514)
Colorado (602)
Connecticut (616)
Delaware (436)
Europe (87063)
Florida (2142)
Georgia (450)
Hawaii (3)
Idaho (63)
Illinois (1165)
India (101)
Indiana (637)
Iowa (24)
Japan (601)
Kansas (134)
Kentucky (52)
Louisiana (59)
Maine (78)
Maryland (1673)
Massachusetts (10117)
Michigan (378)
Minnesota (762)
Mississippi (7)
Missouri (153)
Montana (33)
Nebraska (30)
Nevada (151)
New Hampshire (84)
New Jersey (3692)
New Mexico (30)
New York (3716)
North Carolina (1775)
North Dakota (9)
Northern California (7137)
Ohio (420)
Oklahoma (23)
Oregon (40)
Pennsylvania (2806)
Puerto Rico (31)
Rhode Island (52)
South America (1128)
South Carolina (89)
South Dakota (2)
Southern California (5610)
Tennessee (232)
Texas (2267)
United States (49799)
Utah (422)
Vermont (2)
Virginia (344)
Washington D.C. (81)
Washington State (1124)
West Virginia (4)
Wisconsin (133)
Wyoming (2)
737,511 Results for "spinal elements inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Spinal Elements Expands Ventana® Platform with FDA 510(k) Clearance and First Cases of Ventana® A ALIF System
March 19, 2026
·
3 min read
Press Releases
Spinal Resources, Inc. Awarded Second U.S. Patent for Multi-Diameter Spinal Fixation Rod, Establishing a Layered IP Position
May 8, 2026
·
3 min read
Press Releases
Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
July 2, 2026
·
7 min read
Press Releases
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
June 4, 2026
·
13 min read
Press Releases
Neuronoff Implants First Patient in DOD-Funded Trial of Injectrode® for Neurogenic Bladder in Spinal Cord Injury
June 7, 2026
·
6 min read
Press Releases
NeuroLife® Launch Brings Non-Invasive Technology Aimed at Restoring Hand and Arm Movement After Stroke and Spinal Cord Injury
June 25, 2026
·
3 min read
Press Releases
Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury
July 1, 2026
·
7 min read
Neuroscience
NervGen’s Peptide Achieves Nervous System Repair in Phase II Spinal Cord Injury Study
NervGen will meet with the FDA early next year to align on a regulatory path forward for NVG-291 in chronic spinal cord injury.
November 24, 2025
·
2 min read
·
Tristan Manalac
Press Releases
New study could improve testing and treatment for rare brain, spinal cord, and eye cancers
May 21, 2026
·
4 min read
Approvals
Novartis Expands Spinal Muscular Atrophy Gene Therapy Market With FDA’s Itvisma Greenlight
The FDA approved an intrathecal form of Novartis’ spinal muscular atrophy gene therapy Zolgensma on Monday, broadening access to patients two years and older in what one Stanford Medicine professor called a “game changing advance” for the field.
November 25, 2025
·
3 min read
·
Heather McKenzie
1 of 73,752
Next
